Bortezomib Completed Phase 1 Trials for Multiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00153933Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma